Picard Medical, INC

Picard Medical has received acceptance from NYSE American for its plan to regain compliance with continued listing standards, allowing it to maintain its listing while executing strategic initiatives.

Picard Medical, Inc. announced that its stockholders approved all matters put forth at the Annual Meeting, including director elections, executive compensation, and a reverse stock split.

Picard Medical releases annual stockholder presentation detailing strong Q1 revenue growth, product development milestones for the Emperor platform, and proposals for the upcoming 2026 Annual Meeting.

Picard Medical discusses Q1 growth, next-gen artificial heart tech, and proposals including a reverse stock split to address NYSE listing concerns.

Picard Medical releases its 2026 Annual Stockholder Presentation highlighting business progress, product development, and upcoming meeting proposals.

Picard Medical, Inc. announced the appointment of Dr. Joe Xiao to its Board of Directors, effective June 23, 2026.

Picard Medical reports Q1 2026 revenue growth alongside significant liquidity challenges and a going concern warning.

Picard Medical, Inc. reported increased revenue and a significant cash infusion from its recent IPO, but continued to post substantial net losses for the nine months ended September 30, 2025.

Picard Medical, Inc. completed its Initial Public Offering, raising $17 million in gross proceeds, despite reporting a significant increase in net loss and ongoing operational challenges for the first half of 2025.

Picard Medical posted a larger 2025 net loss amid modest revenue growth, completed a $19.6M IPO and issued $15M of senior secured notes with attached warrants as auditors flagged going-concern risk.

Picard Medical outlines 2026 business performance, product development, and key proposals for the upcoming Annual Stockholder Meeting.

Picard Medical has released a pre-recorded presentation ahead of its 2026 Annual Meeting, detailing business progress, product development, and stockholder proposals.

Picard Medical, Inc. is holding its annual stockholder meeting on July 17, 2026, to vote on critical proposals including a reverse stock split, the creation of Class B stock, director elections, and executive compensation.

Picard Medical, Inc. will hold a special meeting on March 10, 2026, to vote on increasing its authorized common stock from 150 million to 300 million shares to support future capital needs and strategic initiatives.

Picard Medical, Inc. will hold a special meeting on October 10, 2025, to seek stockholder approval for an amendment to its 2021 Equity Incentive Plan, increasing available shares to 18 million and including warrants as award types.

Picard Medical, Inc. has filed a registration statement for the resale of up to 16,211,479 shares of its Common Stock by selling stockholders.

Picard Medical, Inc. is offering up to 21.1 million shares of common stock and associated warrants to raise approximately $9.1 million, facing significant net losses and a going concern doubt.

Picard Medical, Inc. has filed an S-1 registration statement detailing an offering of common stock, pre-funded warrants, and common warrants.

Picard Medical, Inc. filed an S-1/A registration statement for the resale of up to 17,000,000 shares of common stock by selling stockholders, including shares from senior secured notes and warrants, with no direct proceeds to the company from these sales.

Picard Medical, Inc. filed an S-1 registration statement for the resale of up to 17 million shares of common stock by selling stockholders, stemming from a recent $15 million senior secured notes and warrants private placement.

Picard Medical, Inc. is pursuing an initial public offering of 4.25 million shares at $3.50-$4.50 per share to fund operations and product development, despite a history of significant net losses and substantial doubt about its ability to continue as a going concern.

Versa Capital Management and associated entities have reported a zero percent beneficial ownership stake in Picard Medical, Inc.

Hudson Bay Capital Management LP and Sander Gerber have disclosed a beneficial ownership of 8.68% in Picard Medical, Inc., primarily through warrants.

A group of entities and an individual associated with Versa Capital Group have reported beneficial ownership of 10.8% of Picard Medical, Inc.'s common stock.